HCC

The success of chimeric antigen receptor T-cell therapy observed in hematologic malignancies has not yet translated into the solid tumor setting; however, efforts continue to try to bring this new modality into the treatment paradigm for solid tumors, including pancreatic cancer. 

Because of the complex nature of diagnosing, treating, and managing hepatocellular carcinoma, a multidisciplinary approach in the community setting can provide optimal care to patients with the disease.

An analysis of the genotyping of tumor tissue samples from patients with hepatocellular carcinoma identified frequent alterations and potentially actionable mutations in cases of HCC, and helped to confirm the clinical utility of next-generation sequencing testing for matching patients to targeted therapies and immunotherapies.

Michael A. Morse, MD, FACP, MHS, highlights the latest ongoing research in HCC and predicts what future treatment might look like in this field.

Kevin Staveley-O’Carroll, MD, PhD, discusses one of the challenges in treating patients with hepatocellular carcinoma and shares what he thinks are the next steps in overcoming this challenge.

The healthcare community is still awaiting a response from the Centers for Medicare & Medicaid Services to the opposition of the agency’s proposal to substantially revise the Medicare Part D protected drug classes.

Overtreating men 70 years or older with prostate cancer cost Medicare more than $1.2 billion from 2004 to 2007, according to the results of a retrospective study using the Surveillance, Epidemiology, and End Results–Medicare linked database.

During a <em>Targeted Oncology </em>live case-based peer perspectives program, Ruth He, MD, PhD, discussed her strategies for treating patients with liver cancer as more therapeutic options enter the landscape.

Masatoshi Kudo, MD, PhD,&nbsp;discusses the results from the REFLECT trial and an analysis presented at the 2019 Gastrointestinal Cancers Symposium, as well as other research currently ongoing for this patient population.

Daneng Li, MD,&nbsp;sheds light on some of the currently available regimens and ongoing research efforts being conducted in HCC and NETs.

Merck,&nbsp;the developer of pembrolizumab, has announced that the coprimary endpoints of the&nbsp;KEYNOTE-240 trial were not met, as adding the agent&nbsp;to best supportive care failed&nbsp;to improve&nbsp;progression-free or overall survival in patients with advanced hepatocellular carcinoma who were previously treated with systemic therapy.

Josep M. Llovet, MD, PhD, discussed the available treatment options for patients with hepatocellular carcinoma.

Although immune checkpoint inhibition&ndash;related hepatotoxicity is a rare occurrence, it leads to ICI treatment discontinuation in more than two-thirds of affected patients, according to the results of a retrospective study presented at the American Association for the Study of Liver Diseases&rsquo; 2018 Liver Meeting.

Using regorafenib after hepatocellular carcinoma progression on sorafenib in the post&ndash;liver transplantation setting produced overall survival effects similar to those of patients without liver transplant, according to results presented at the American Association for the Study of Liver Diseases&rsquo; 2018 Liver Meeting.

A look back at all the&nbsp;FDA news&nbsp;in oncology from the month of&nbsp;January 2019, including several new approvals, breakthrough therapy designations, and a partial clinical hold.

The combination of sorafenib and modified FOLFOX demonstrated encouraging efficacy in a small phase II study, but some patients exhibited moderate hepatoxicity, according to investigators from the Massachusetts General Hospital Cancer Center.